科研之友
微信
新浪微博
Facebook
分享链接
摘要
In this issue of Blood, Pfeifer et al have determined that CDKN2A/2B deletions are "a strong and independent prognostic marker for predicting risk of relapse and overall survival" when adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) are treated with both imatinib and allogenic stem cell transplantation (aSCT).(1)
- 出版日期2018-3-29
